AlphaStocks
4.7
Weak

Neurocrine Biosciences Inc (NBIX)

As of Sep 18, 2026, Neurocrine Biosciences Inc (NBIX) scores 4.7/10 on AlphaStocks' five-model composite, #119 of 168 Health Care stocks. At $152, NBIX trades 11% above its model fair value of $136.

Health Care / Biotechnology

S&P MidCap 400

$151.83

Below average on several measures. Research carefully.

Weak

Score based on 4 of 5 models — moderate confidence

Data as of Sep 18, 2026

#119out of 168 in Health Care

Is NEUROCRINE BIOSCIENCES INC a Good Investment in 2026?

NEUROCRINE BIOSCIENCES INC (NBIX) scores 4.7 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates NEUROCRINE BIOSCIENCES INC as Attractive (5/9). However, the Graham model rates it Caution — Significantly above fair value. NEUROCRINE BIOSCIENCES INC currently trades 11% above its estimated fair value of $136. NEUROCRINE BIOSCIENCES INC ranks #119 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E32.5ROE15.3Market Cap16B

Estimated Fair Value

$136.3011% above

Trading above estimated fair value. Rapid eps growth (42%) partially justifies the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 2.9 · Fast Grower

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is NEUROCRINE BIOSCIENCES INC (NBIX) a good investment?
As of Sep 18, 2026, Neurocrine Biosciences Inc (NBIX) scores 4.7/10 on AlphaStocks' five-model composite, #119 of 168 Health Care stocks. At $152, NBIX trades 11% above its model fair value of $136. That score is below average, suggesting caution.
What is NEUROCRINE BIOSCIENCES INC's Piotroski F-Score?
NEUROCRINE BIOSCIENCES INC's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is NBIX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $136, NBIX appears overvalued. The stock currently trades 11% above its estimated fair value. Trading above estimated fair value. Rapid eps growth (42%) partially justifies the premium.
How does NBIX compare to other Health Care stocks?
NEUROCRINE BIOSCIENCES INC ranks #119 out of 168 stocks in the Health Care sector, placing it in the top 71% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about NBIX?
AlphaStocks evaluates NBIX using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Caution; Lynch: Neutral. These models are combined into a single composite score of 4.7/10.

Similar Stocks

ABBVINCYHRMY

Compare NBIX with

ABBV vs NBIXINCY vs NBIXHRMY vs NBIX

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer